课题基金 / 基金详情

Targeted therapy of gastrointestinal cancer using human anti-CEA antibody

Targeted therapy of gastrointestinal cancer using human anti-CEA antibody
人抗CEA抗体靶向治疗胃肠癌
批准号:
17591421
负责人:
TANAKA Toshihiro
金额:
$2.24万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006

项目摘要

项目成果

TANAKA Toshihiro的其他基金

相似基金

相关文献

中文摘要
翻译
我们构建了一个纤维修饰的Ad5载体(Adv-FZ33),该载体将葡萄球菌蛋白a衍生的igg结合域(Z33)插入到knob蛋白的HI环中。我们在体外和体内水平上评估了使用这种修饰载体的抗cea抗体复合物对cea阳性胃癌的重靶向程度和治疗效果。与抗cea单抗结合的Adv-FZ33载体感染后,LacZ基因的体外表达量比与对照单抗结合的载体高约20倍。ax3cap - fz33是一种Adv-FZ33衍生载体,表达一种治疗性基因,即大肠杆菌尿嘧啶磷酸核糖基转移酶(UPRT),可将5FU直接转化为5-氟吡啶单磷酸。当ax3cap - fz33与抗cea单抗结合时,5FU对胃癌细胞的细胞毒性增强(IC_<50>值的19.7倍)。接下来,我们研究了Ax3U…More P-FZ33结合抗cea mAb + 5FU对腹膜播散性胃癌小鼠的生存影响。ax3cap - fz33 /anti-CEA mAb/5FU组的中位生存时间显著长于PBS和5FU治疗组(p<0.01,与PBS和5FU治疗组相比)。此外,我们还检测了哪一种IgG亚型对Adv-FZ33和抗cea单抗介导的基因传递有效。BIACORE分析显示,人IgG1和IgG4对蛋白A的亲和常数(Ka)比小鼠IgG1高1000倍,而仅比小鼠IgG2a或IgG3高10倍。在表达cea的细胞中,Adv-FZ33与任何亚型的抗cea人IgG的转基因表达量明显高于任何类型的病毒-抗cea小鼠IgG的转基因表达量。特别是,人IgG4介导的转导效率比小鼠IgG1提高了200倍。我们发现Ab和蛋白A的反应性在Adv-FZ33传递Ab依赖基因的过程中起着关键作用。少
英文摘要
We constructed a fiber modified Ad5 vector (Adv-FZ33) in which an IgG-binding domain (Z33) derived from staphylococcal protein A was inserted into the HI loop of knob protein. We evaluated on both in vitro and in vivo levels the extent of retargeting towards and therapeutic effectiveness against CEA-positive gastric cancers when using the anti-CEA antibody complex with this modified vector. In vitro LacZ gene expression after infection with Adv-FZ33 vectors conjugated to anti-CEA mAb was approximately 20 times higher than that obtained with vector conjugated to the control mAb. We generated Ax3CAUP-FZ33, which is an Adv-FZ33 derivative vector expressing a therapeutic gene, namely E. coli uracil phosphoribosyltransferase (UPRT) which converts 5FU directly to 5-fluorouridine monophosphate. When conjugated with the anti-CEA mAb, Ax3CAUP-FZ33 enhanced the cytotoxicity of 5FU (19.7-fold in terms of IC_<50> values) against gastric cancer cells. Nextl, we examined the survival effects of Ax3U … More P-FZ33 conjugated with anti-CEA mAb plus 5FU in mice with peritoneal disseminated gastric cancer. The median survival time of the Ax3CAUP-FZ33/anti-CEA mAb/5FU group was significantly longer than those of the PBS and 5FU only treatment groups (p<0.01, versus PBS and 5FU only groups).Furthermore, we examined which subtype of IgG was effective on gene delivery mediated by Adv-FZ33 and anti-CEA mAb. BIACORE analysis showed that human IgG1 and IgG4 had 1,000-fold higher affinity constants (Ka) for protein A compared with mouse IgG1, whereas only 10-fold higher than mouse IgG2a or IgG3. In CEA-expressing cells, the transgene expression using Adv-FZ33 and any subtype of anti-CEA human IgG was significantly increased compared with combinations of any type of virus-anti-CEA mouse IgG. Especially, human IgG4 mediated transduction efficiency showed 200-fold enhancements compared with mouse IgG1. We found that the reactivity of Ab and protein A played a key role in the Ab dependent gene delivery by Adv-FZ33. Less
期刊论文(22)
专著(0)
科研奖励(0)
会议论文
Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
将细胞毒性 T 淋巴细胞和/或自然杀伤细胞重新靶向具有抗 CEA 抗体活性的表达 CEA 的肿瘤细胞。
DOI: --
发表时间: 2005
期刊: Anticancer Res. 25(6)
影响因子: --
作者: [Kuroki, Ma., Hachimine, K., Huang J., Shibaguchi, H., Kinugasa, T., Maekawa, S., Kuroki, Mo.]
通讯作者: Mo.
Recent Development in Gene Therapy
基因治疗的最新进展
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [Tanaka T, Hamada H, Kuroki Ma, et al.]
通讯作者: et al.
Targeting of cancer gene therapy with antibodies or their genes against tumor-associated antigens.
使用抗肿瘤相关抗原的抗体或其基因来靶向癌症基因治疗。
DOI: --
发表时间: 2005
期刊: Gene Ther.Mol.Biol. 9
影响因子: --
作者: [田中純子, 片山恵子, Kuroki M.]
通讯作者: Kuroki M.
Targeting of cacner gene therapy with antibodies or their genes against tumor-associated antigens.
使用抗肿瘤相关抗原的抗体或其基因来靶向癌症基因治疗。
DOI: --
发表时间: 2005
期刊: Gene Ther. Mol. Biol. 9(A)
影响因子: --
作者: [Kuroki Ma, et al.]
通讯作者: et al.
共 12 条
    IL-35 associate with the Th2 response and the differentiation of Tregs in type 1 AIP.
    • 批准号:
      19K17476
    • 项目类别:
      Grant-in-Aid for Early-Career Scientists
    • 资助金额:
      $2.75万
    • 财政年份:
      2019
    • 负责人:
      TANAKA Toshihiro
    • 依托单位:
    Mechanism elucidation of interfacial tension change due to chemical reaction between molten iron and molten slag and construction of quantitative estimation model
    • 批准号:
      17H03437
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.9万
    • 财政年份:
      2017
    • 负责人:
      TANAKA Toshihiro
    • 依托单位:
    Design of a process producing joint materials by using surface porous gradient structure
    • 批准号:
      22656173
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.26万
    • 财政年份:
      2010
    • 负责人:
      TANAKA Toshihiro
    • 依托单位:
    Pancreas-specific antibody production and development of pancreatic cancer therapy using virus vector
    • 批准号:
      22501054
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.66万
    • 财政年份:
      2010
    • 负责人:
      TANAKA Toshihiro
    • 依托单位:
    国内基金
    海外基金
    基于 CeA-DMV-Vagus 环路研究电针刺激四关穴缓解帕金森病的作用机 制
    • 批准号:
      JCZRLH202600541
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    基底外侧杏仁核敏化介导PVT-CeA神经环路长时程增强参与失眠慢性化的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      高东
    • 依托单位:
    Eph-Ephrin 信号通路通过调控 PVT→CeA 神经环路干预双相情感障碍共病睡眠障碍发生的机制研究
    不同强度电针通过CeA/PVN-CRH神经元差异驱动脾神经/HPA轴调控MIRI后心肌巨噬细胞免疫重塑的机制研究
    • 批准号:
      82505726
    • 项目类别:
      青年科学基金项目(C类)
    • 资助金额:
      30.00万元
    • 批准年份:
      2025
    • 负责人:
      白桦
    • 依托单位: